Compare VNCE & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNCE | SNTI |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 29.8M |
| IPO Year | 2013 | 2021 |
| Metric | VNCE | SNTI |
|---|---|---|
| Price | $6.84 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.17 | ★ $8.50 |
| AVG Volume (30 Days) | 138.9K | ★ 179.4K |
| Earning Date | 04-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.45 | 77.31 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $300,007,000.00 | N/A |
| Revenue This Year | $5.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.22 | ★ N/A |
| Revenue Growth | ★ 2.23 | N/A |
| 52 Week Low | $1.19 | $0.77 |
| 52 Week High | $5.90 | $3.03 |
| Indicator | VNCE | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 80.76 | 46.58 |
| Support Level | $2.34 | $0.86 |
| Resistance Level | N/A | $1.03 |
| Average True Range (ATR) | 0.48 | 0.06 |
| MACD | 0.16 | -0.00 |
| Stochastic Oscillator | 89.87 | 30.37 |
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale, Vince Direct-to-consumer, and Rebecca Taylor and Parker segment. It operates its e-commerce business through its website. Majority of its revenue generated from Vince Wholesale segment.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).